

NOVADEL PHARMA INC  
Form 8-K  
August 09, 2006

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported) August 8, 2006**

**NOVADEL PHARMA INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware  
(State or other jurisdiction of  
incorporation or organization)**

**001-32177  
(Commission File No.)**

**22-2407152  
(I.R.S. Employer  
Identification No.)**

**25 Minneakoning Road**

**Flemington, New Jersey 08822**

(Address of principal executive offices) (Zip Code)

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

(908) 782-3431

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**Item 8.01 Other Events**

On August 8, 2006, NovaDel Pharma Inc. issued a press release announcing the initiation of a clinical trial for its proprietary formulation of zolpidem oral spray. The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

- 99.1 Press release of NovaDel Pharma Inc. dated August 8, 2006, titled NovaDel Announces Initiation of Clinical Trial of Zolpidem Oral Spray - New Drug Application Expected in 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovaDel Pharma Inc.**

By: /s/ Michael E. Spicer  
Name: Michael E. Spicer  
Title: Chief Financial Officer

Date: August 9, 2006